Bruce Burnett

Company: InflaRx

Job title: VP, Head of Medical Affairs

Seminars:

Discussing Vilobelimab Phase III Study in Severe COVID-19 8:20 am

Reviewing how complement fragment C5a is activated by SARS-CoV-2 infection leading to neutrophil activation, reactive oxygen species generation, NETosis, release of tissue factor and fibrin formation, which contributes to a microangiopathy with thrombosis Exploring Vilobelimab, a first-in-class anti-C5a monoclonal antibody, binds C5a with high affinity clearing it from circulation Evaluating how Phase III results in…Read more

day: Day Two